Cargando…

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

Detalles Bibliográficos
Autores principales:	Andersen, TI, Skovlund, E, Bukholm, IK, Jacobsen, U, Kåresen, R, Erikstein, B, Nesland, J, Børresen-Dale, A-L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300856/ http://dx.doi.org/10.1186/bcr158

Ejemplares similares

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Screening breast cancer patients for Norwegian ATM mutations
por: Laake, K, et al.
Publicado: (2000)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Screening breast cancer patients for Norwegian ATM mutations
por: Laake, K, et al.
Publicado: (2000)

Genetic variants of CYP19 (aromatase) and breast cancer risk
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

p16(INK4A) as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy
por: Geisler, S, et al.
Publicado: (2000)

Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
por: Yoshimura, Noriko, et al.
Publicado: (2004)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

X chromosome inactivation pattern in female patients with breast cancer
por: Kristiansen, M, et al.
Publicado: (2000)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Role of TP53 polymorphisms in sub-Saharan mucosal cancers
por: Buonaguro, Franco M, et al.
Publicado: (2010)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
por: Alsner, J, et al.
Publicado: (2000)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection
por: Due, EU, et al.
Publicado: (2005)

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
por: Helland, A., et al.
Publicado: (1998)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, David M, et al.
Publicado: (2012)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, DM, et al.
Publicado: (2012)

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
por: Drageset, V, et al.
Publicado: (2005)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

Comparing ion torrent with pyrosequencing and Sanger sequencing for the detection of TP53 mutations in colorectal cancer
por: Doyle, Brendan, et al.
Publicado: (2014)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming project
por: Mahendran, K, et al.
Publicado: (2012)

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
por: Smith-Sørensen, B., et al.
Publicado: (1998)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

TP53 and p16INK4A mutations in adult-T cell leukemia/lymphoma (ATL) in Bahia (Brazil)
por: Magalhães, Marcelo, et al.
Publicado: (2011)

Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia
por: Vilas–Zornoza, Amaia, et al.
Publicado: (2011)

Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
por: Voropaeva, Elena N., et al.
Publicado: (2019)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
por: Silwal-Pandit, Laxmi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g6bmn3vdog86opeog07g3n1ji8